Encouraging a Pull incentive in the US: Now is the time for a note from you or your company

Dear All:

You are doubtless now familiar with all the reasons why we need pull incentives for AMR-related products (as background, see this blog). We don’t yet have anything beyond the US GAIN act and it alone will not suffice.

In the US, there are discussions this week in the House of Representatives on reauthorizing PAHPA, the Pandemic and All-Hazards Preparedness Reauthorization Act. Language about market entry rewards (specifically, Transferable Conveyance Awards, TCAs, the new language for transferable exclusivity vouchers) has been in and out of the revised Act, but is currently NOT included.

Although TCAs are not perfect, they appear to be the best way for the US to implement something that approximates the idea of a Market Entry Reward (MER) that was proposed by DRIVE-AB for AMR-related products. If implemented with suitable care, it seems obvious that you could use a TCA to provide the type of delinked payments that are at the heart of the MER idea. If you agree with this viewpoint, today would be a really good day for you (or your company’s CEO) to send a note (separately) to any or all of the the staffers working for these representatives:

  • Rep. Doris Matsui (D-CA): megan.herber@mail.house.gov
  • Rep. Anna Eshoo (D-CA): rachel.fybel@mail.house.gov
  • Rep. Tony Cardenas (D-CA): Jacqueline.Usyk@mail.house.gov
  • Rep. Diane DeGette (D-CO): michelle.greenhalgh@mail.house.gov
  • Rep. Brett Guthrie (R-KY): sophie.trainor@mail.house.gov
  • Rep .Leonard Lance (R-NJ): Robert.Butora@mail.house.gov
  • Rep. Chris Collins (R-NY): charlotte.pineda@mail.house.gov
  • Rep. Marsha Blackburn (R-TN): meghan.stringer@mail.house.gov

David Shlaes has posted a good set of talking points on his Perfect Storm blog. You could use those ideas as well as the materials cited above to help you write a brief message regarding your work in this area, your geography (if relevant to the given Representative), your concern about the negative economics of work in this area, and the value that a Pull incentive such as the TCA would have for you or your company would be appropriate.  

Separately, see the Upcoming Meetings list … a detailed summary from last summer’s NIAID PK-PD workshop has now been published.

All best wishes, –jr

John H. Rex, MD | Chief Medical Officer, F2G Ltd. | Expert-in-Residence, Wellcome Trust. Follow me on Twitter: @JohnRex_NewAbx. See past newsletters and subscribe for the future: http://amr.solutions/blog/

Upcoming meetings of interest to the AMR community:


Fireside Chat with BARDA’s Branch Chief for Antimicrobials

Note: Be sure to take advantage of the BARDA Industry Day(s) event that occurs Monday-Tuesday of this coming week … see newsletter and forward calendar for details. Dear All, In what could be called Part 2 of Excellent 2023 ASM/ESCMID Talks (read the newsletter on Jen Cohen’s talk on how manufacturing underpins both access and

Japan Pulls for Pandemic Preparedness: Nikkei FT Conference

Dear All, As we discussed in the 5 Nov 2023 “Pulling for Pandemic Preparedness” newsletter, AMR is a global threat: resistance in one part of the world can suddenly appear in your hospital. As an example of that sort of threat, Jason Gale’s 30 Oct 2023 newsletter entitled “Untreatable Typhoid Should Make You Worry About Poop”

Pulling for Pandemic Preparedness

Dear All, This evening I’d like to bring together several relatively recent reports and note how all of them focus in one way or another on Pulling for Pandemic Preparedness … perhaps we can call this the Rule of 3 Ps. And as an aside, I’ll note that I learned the Rule of 4 Ps

PACE: A new £30m fund for AMR innovation

Dear All, Exciting additional news merits two newsletters in one day! I’ll keep it brief and quote directly from the website: “Innovate UK, LifeArc, and Medicines Discovery Catapult (MDC) have joined forces to create PACE (Pathways to Antimicrobial Clinical Efficacy), a £30 million initiative supporting early-stage innovation against antimicrobial resistance (AMR) to save lives. PACE has today (19 October 2023) announced

Scroll to Top